title: Compulsory licensing in favor of the patentholders of dependent pharmaceutical inventions
metadata.name: dc.contributor.author
metadata.value: Vorozhevich, Arina S.
metadata.lang: -
metadata.name: dc.date.accessioned
metadata.value: 2021-04-20T17:32:30Z
metadata.lang: -
metadata.name: dc.date.available
metadata.value: 2021-04-20T17:32:30Z
metadata.lang: -
metadata.name: dc.date.issued
metadata.value: 2021-03
metadata.lang: -
metadata.name: dc.identifier.citation
metadata.value: Vorozhevich, Arina S. 2021. “Compulsory licensing in favor of the patentholders of dependent pharmaceutical inventions”. Vestnik of Saint Petersburg University. Law 1: 73–98.
metadata.lang: en_GB
metadata.name: dc.identifier.other
metadata.value: https://doi.org/10.21638/spbu14.2021.105
metadata.lang: -
metadata.name: dc.identifier.uri
metadata.value: http://hdl.handle.net/11701/28063
metadata.lang: -
metadata.name: dc.description.abstract
metadata.value: The article analyzes the conditions for issuing a compulsory license in favor of the patent holders
  of dependent pharmaceutical inventions on the basis of Paragraph 2, Article 1362 of the
  Russian Civil Code. The criteria for the relevance of a dependent invention to important technical
  advancements with significant economic advantages are disclosed. An analysis of the
  emerging Russian court practice on the issuance of compulsory licenses in the pharmaceutical
  market, meanwhile, showed that Russian courts lack a clear understanding of when a patent
  holder can and cannot apply for a compulsory license. The author proves that compulsory
  licensing is an effective mechanism to prevent abuse of the right (first of all, to standard-essential
  patent) in the markets of complex innovations (IT, electronics and telecommunications).
  At the same time, its implementation on the pharmaceutical market can lead to negative consequences:
  discourage pharmaceutical companies to invest in the development of new drugs,
  register breakthrough drugs in Russia; reduce foreign investment in the pharmaceutical sector.
  In this case, the provision of compulsory licenses should be interpreted as an exceptional
  tool. The issuance of a compulsory license in favor of the owner of the dependent invention
  can be justified only if such an invention represents a genuine innovation, an important step
  in the development of pharmaceuticals. The licensee must offer the market a new drug with
  improved characteristics: increased therapeutic efficacy and (or) safety, which has no available
  alternatives.
metadata.lang: en_GB
metadata.name: dc.language.iso
metadata.value: ru
metadata.lang: en_GB
metadata.name: dc.publisher
metadata.value: St Petersburg State University
metadata.lang: en_GB
metadata.name: dc.relation.ispartofseries
metadata.value: Vestnik of St Petersburg University. Law;Volume 12; Issue 1
metadata.lang: -
metadata.name: dc.subject
metadata.value: patent rights
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: patent holder
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: patent misuse
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: compulsory license
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: pharmaceuticals
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: important technical advancement
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: dependent invention
metadata.lang: en_GB
metadata.name: dc.title
metadata.value: Compulsory licensing in favor of the patentholders of dependent pharmaceutical inventions
metadata.lang: en_GB
metadata.name: dc.type
metadata.value: Article
metadata.lang: en_GB
resources.filename: 73-98.pdf
resources.url: https://dspace.spbu.ru/bitstream/11701/28063/1/73-98.pdf
resources.format: Adobe PDF
resources.size: 712,36 kB